



# EasyOne Pro and EasyOne Pro LAB Spirometry and complete PFT reimbursement

## Return on investment\*

Tests per month	Revenue per month	Payoff (months)
16	\$2,416	9
32	\$4,832	4
48	\$7,248	3

\*Based on average reimbursement of \$151 per lung function session (total of 94060, 94729, 94727). See the Reimbursement Disclaimer below.

## CPT Coding

Code*	Description	2024 National Average Reimbursement
94010	Spirometry	\$29
94060	Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration	\$42
94375	Respiratory flow volume loop	\$42
94729	Diffusing capacity (eg, carbon monoxide, membrane)	\$61
94727	Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes	\$48
94070	Bronchospasm provocation evaluation, multiple spirometric determinations as in 94010, with administered agents (eg, antigen[s], cold air, methacholine)	\$68
94200	Maximum breathing capacity, maximal voluntary ventilation	\$16

\*These reimbursements are based on United States Medicare Average as of January 2024. Subject to change at any time. Please refer to your local provider for actual reimbursement rates in your area. See also the Reimbursement Disclaimer below.

### Reimbursement Disclaimer:

n d d Technologies does not represent or warrant that any of the information provided in this sheet is correct or that third-party insurance carrier reimbursement is available for any of the referenced procedures. This reimbursement information is based on averages that may vary over time or from place to place. All coding and reimbursement information are subject to change without notice. Different rates may apply to your situation. This information does not constitute professional or legal advice on reimbursement and should not be relied on as definitive. Before filing any claims, it is the provider's sole responsibility to verify current requirements and policies with the applicable payer.



## Indications for DLCO Measurement

- Evaluation and follow-up for diseases which involve lung parenchyma (e.g., those associated with dusts, drug reactions, or sarcoidosis)
- Evaluation and follow-up of emphysema
- Differentiating among chronic bronchitis, emphysema, and asthma
- Evaluation of pulmonary involvement in systemic disease
- Evaluation of cardiovascular diseases
- Prediction of arterial desaturation during exercise in some patients with lung disease
- Evaluation and quantification of impairment and disability associated with interstitial lung diseases and emphysema
- Evaluation of the pulmonary effects of chemotherapy agents or other drugs known to induce pulmonary dysfunction
- Evaluation of pulmonary hemorrhage
- As an early indication of certain pulmonary infections that cause diffuse pneumocystis (e.g., pneumocystis pneumonia)

## Common ICD-10 Codes

Indication	ICD 10-CM Code
<b>Chronic airway obstruction</b>	
Chronic obstructive pulmonary disease, unspecified	J44.9
<b>Chronic obstructed asthma</b>	
Chronic obstructive pulmonary disease with acute lower respiratory infection	J44.0
Chronic obstructive pulmonary disease with (acute) exacerbation	J44.1
Chronic obstructive pulmonary disease, unspecified	J44.9
<b>Acute respiratory failure</b>	
Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	J96.00
Respiratory failure, unspecified, unspecified whether with hypoxia or hypercapnia	J96.90
Respiratory failure, unspecified with hypoxia	J96.01
Acute respiratory failure with hypoxia	J96.02
Acute respiratory failure with hypercapnia	J96.91
Respiratory failure, unspecified with hypoxia	J96.92
Respiratory failure, unspecified with hypercapnia	
<b>Other respiratory indications</b>	
Periodic breathing	R06.3
Dyspnea, unspecified	R06.00
Other forms of dyspnea	R06.09
Snoring	R06.83
Other abnormalities of breathing	R06.8